Skip to main content
Clinical Trials/IRCT20210514051289N1
IRCT20210514051289N1
Completed
Phase 3

Effect of Angiotensin-converting enzyme and ß-blockers on the prognosis of patients with severely isolated brain trauma

Esfahan University of Medical Sciences0 sites96 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
S06.2X
Sponsor
Esfahan University of Medical Sciences
Enrollment
96
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Severe trauma
  • Age greater than or equal to 18 years
  • No previous use of beta\-blockers or Angiotensin\-converting enzyme at home
  • Informed consent of the patient's guardian or legal guardian to admit the patient to the study

Exclusion Criteria

  • Renal artery stenosis
  • Chronic kidney disease
  • History of drug allergy
  • Hyperkalemia
  • High creatinine
  • Bradycardia or heart block

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
The Effect of Angiotensin Convetring Enzyme Inhibitor on the Quality of Life of Non Hospitalized Patients With Cancer Cachexia in Shiraz University ClinicsGastric cancer.Malignant neoplasm of stomach
IRCT2014050511375N3Shiraz University of Midical Sciences40
Completed
Not Applicable
Effect of Angiotensin Converting Enzyme Inhibition (ACEI) on C-Reactive Protein (CRP) Levels: The Ramipril CRP Randomized Evaluation (4R Trial)Healthy volunteers with elevated levels of C-Reactive proteinCirculatory System
ISRCTN31129526Sanofi-Aventis (Canada)400
Recruiting
Not Applicable
Benefit and Harm of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in COVID-19 Patients: A Review Protocol of Systematic Review and Meta-AnalysisThere is a controversial debate regarding how to treat cardiovascular disease in COVID-19 confirmed patients. Ones documented that ACE inhibitor may increase risk of fatal COVID-19 by serving entry site for this virus, on contrary ones documented that ACEi and/or ARB may be beneficial for Acute Lung Injury and cardiovascular protection.
JPRN-UMIN000041430Faculty of Medicine, Universitas Airlangga
Not yet recruiting
Not Applicable
Prognostic impact of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers in cancer patientsCancer Patients
JPRN-UMIN000052284Yokohama City University Graduate School of Medicine
Completed
Not Applicable
Pharmacogenetics of angiotensin converting enzyme and relationships with angiotensin converting enzyme activity in Thai populatioACE inhibitor&#45induced coughpharmacogeneticsangiotensin converting enzyme activityACE
TCTR20180718001Faculty of Medicine, Thammasat University100